Prollenium Medical Technologies Inc. Reacquires Ovita® HV Brand for Global Distribution
AURORA, ON, June 24, 2013 /CNW/ – Prollenium Medical Technologies Inc.
is proud to announce the reacquisition of the rights to Ovita® HV, a
hyaluronic based dermal filler. Ovita® is a high viscosity, non-animal
based, biodegradable gel that treats deep and more pronounced lines and
wrinkles, particularly oral commissures and nasolabial folds. The brand
is produced by Prollenium and will be distributed worldwide.
In 2010, Prollenium entered a partnership with international
pharmaceutical company Valeant to supply and distribute Ovita® HV.
After years of a successful relationship, the two companies have
mutually ended the agreement putting Ovita® HV back in the hands of
Prollenium. “The agreement with Valeant was very rewarding for
Prollenium and Ovita® HV. The sales and marketing support Valeant
dedicated to Ovita® HV has put the product in the forefront of
customer’s minds providing a great opportunity for us to sustain
business going forward,” says Prollenium’s Senior Vice President Khasha
“Here at Prollenium, we commend Valeant for a job well done promoting
the home grown aspect of Ovita® HV. We are very excited to confirm that
the product will not be discontinued, but will in fact, continue to be
produced in house at our facility in Aurora, Ontario, Canada,” says
Managing Director Ario Khoshbin. Ovita® HV is produced in the only
dermal filler manufacturing facility for tissue reconstruction in
Canada. The facility is also the home of the company’s Sales, Marketing
and R&D teams.
Prollenium is highly dedicated to the research of innovative products to
provide to the marketplace. Reacquiring the rights to Ovita® HV
presents the company with the opportunity to greatly expand this
product line. A new addition, Ovita® HV with Lidocaine, a topical
anesthetic, will be available in the Fall of 2013. In addition to
dermal fillers, Prollenium extends its product offering into the
skincare, revitalization and therapeutic markets worldwide.
For more information, please visit www.prollenium.com
Prollenium Medical Technologies Inc. is a Canadian-based company,
founded in 2002, dedicated to the research, design, manufacture and
distribution of implantable polymers in the
pharmaceutical/dermatological industry. The company is committed to
providing innovative products worldwide that are safe and viable.
Flagship product lines include Revanesse®, Phiderma® and Rheo Vital(TM).
SOURCE Prollenium Medical Technologies Inc.